Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

Annals of Surgery

Volumn 258, Issue 3, 2013, Pages 422-428

  DeMatteo, Ronald P ^a   Ballman, Karla V ^b   Antonescu, Cristina R ^a   Corless, Christopher ^c   Kolesnikova, Violetta ^c   Von Mehren, Margaret ^d   McCarter, Martin D ^e   Norton, Jeffrey ^f   Maki, Robert G ^g   Pisters, Peter W T ^h   Demetri, George D ⁱ   Brennan, Murray F ^a   Owzar, Kouros ^j  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j DUKE UNIVERSITY   (United States)

more..

Author keywords

Gastrointestinal stromal tumor; Imatinib mesylate; Surgery

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CONFERENCE PAPER; DERMATITIS; DIARRHEA; DRUG TOLERABILITY; EDEMA; EXON; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SURGEON; VOMITING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; GENE MUTATION; MITOSIS INDEX; NEOPLASM; NOTE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884512860     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182a15eb7     Document Type: Conference Paper

References (23)

1. Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011; 6:e20294.
2. Joensuu H, DeMatteo RP. Themanagement of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med. 2012; 63: 247-258.
3. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231: 51-58.
4. DeMatteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002; 33: 466-477.
5. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279: 577-580.
6. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299: 708-710.
7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-480.
8. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-1134.
9. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26: 620-625.
10. Blanke CD, Rankin C,Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008; 26: 626-632.
11. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: ameta-analysis of 1,640 patients. J Clin Oncol. 2010; 28: 1247-1253.
12. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008; 112: 608-615.
13. Ng EH, Pollock RE,MunsellMF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992; 215: 68-77.
14. Antonescu CR, SommerG, Sarran L, et al. Association ofKIT exon 9mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res. 2003; 9: 3329-3337.
15. Guo T, Hajdu M, Agaram NP, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res. 2009; 15: 6862-6870.
16. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992; 69: 1334-1341.
17. Miettinen M, Lasota J. Gastrointestinal stromal tumors: reviewon morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006; 130: 1466-1478.
18. Gold JS, Gönen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009; 10: 1045-1052.
19. Rossi S, Miceli R,Messerini L, et al.Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol. 2011; 35: 1646-1656.
20. Debiec-RychterM, Sciot R, Le CesneA, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006; 42: 1093-1103.
21. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008; 26: 5360-5367.
22. Emile JF, Brahimi S, Coindre JM, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2012; 29(3): 1765-1772.
23. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307: 1265-1272.